The Company has a high-calibre Board with the healthcare leadership, corporate strategy, diagnostics development and commercial experience to guide the business towards its vision of becoming a leading Australian-based diagnostics company.

Dr Geoff Cumming | Non-Executive Chairman

Geoff Cumming, BSc (Hons), B. App.Sc, MAICD, MBA, PhD has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Geoff transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Geoff was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals. His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Non-executive Director of Anteo Diagnostics Ltd and was previously Chairman of Sienna Cancer Diagnostics Ltd (ASX:SDX) and a Non-executive Director of Medical Australia Ltd (ASX: MLA).

Dr Irmgard Irminger-Finger | Executive Director & Founding Scientist

Dr Irminger-Finger BSc, MSc, PhD is an experienced chief scientist and internationally recognised expert in tumour biology. She studied molecular biology and biochemistry at the University of Zurich, obtained a master’s in molecular biology and biochemistry and a PhD in molecular genetics. After several years as researcher at the Harvard University, she returned to Geneva, Switzerland. Having obtained a Swiss federal career development award, she focused her research on the molecular pathways at the aging and cancer interface. From 2006-2018 she headed the Molecular Gynaecology and Obstetrics Laboratory at the Geneva University Hospitals with focus on the function of tumour suppressor genes BRCA1 and BARD1. Dr Irminger-Finger built up her reputation as expert on the BRCA1 and BARD1 genes, as author of more than 90 scientific articles, speaker at more than 200 conferences and meetings, editor of scientific journals, member of specific study groups and task forces on cancer, and inventor of several patents that paved the way towards applications in cancer diagnostics and therapy. Dr Irminger-Finger has received numerous awards and grants both for academic research and for her entrepreneurial work as founder of a successful biotech start-up. She is currently Adjunct Professor at the University of Western Australia and was previously Privat Docent at the University and University Hospital of Geneva, head of the Laboratory of Molecular Gynaecology and Obstetrics and Executive Director and founder of BARD1AG SA.

Max Johnston Non – Executive Director

Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world’s largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston’s career also included senior roles with Diageo and Unilever in Australia, Africa and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently Non-Executive Chairman of AusCann Group Holdings Ltd (ASX: AC8) and a Non-Executive Director of PolyNovo Ltd (ASX: PNV), Medical Developments International Ltd (ASX: MVP), CannPal Limited (ASX: CP1) and ProLife Foods NZ. He was a former Non-Executive Director of Enero Group Limited (ASX: EGG) and Non-Executive Chairman of Probiotec Ltd (ASX: PBP).

Philip Powell Non-Executive Director

Mr Philip Powell BComm (Hons), ACA, F.Fin, MAICD, is a Chartered Accountant with extensive experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney and Los Angeles. Mr Powell is currently a Non-Executive Director of PolyNovo Ltd (ASX: PNV), Medical Developments International Ltd (ASX: MVP) and RMA Global Ltd (ASX: RMY).

Professor Allan Cripps Non-Executive Director

Professor Allan Cripps AO PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM is a distinguished academic, clinical scientist and health services leader, having made significant contributions in immunology, diagnostics and health services delivery. From 2005 to 2016, Professor Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research professor at Griffith University, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. Professor Cripps had near 20 years’ experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over $17 million in Government and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management. In 2015 he was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation. Currently Professor Cripps is Independent Chair of the Children’s Health Research Alliance Board. He was previously Non-Executive Director of Research Australia (2005 – 2012) and the Gold Coast Hospital and Health Services Board (2011 – 2017).

Helen Fisher Non-Executive Director

Helen Fisher, BSc, LLB (Hons), LLM, MCom, is a passionate leader with a rare combination of financial expertise and deep knowledge and global networks in the Life Sciences industry. Helen is CEO and Managing Director of Bio Capital Impact Fund and a director of NovellusDx, a personalised cancer diagnostics company. Prior to establishing the Fund, Helen was a partner of Deloitte and led Deloitte’s Life Sciences industry practice in Australia for 5 years, having had many years’ experience in the Life Sciences and Health Care industry. She also specialised in the Financial Services Industry, servicing some of the largest banks and funds in the Funds Management industry and has been involved in setting up a number of large international funds, as well as advised on a number of significant M&A deals. Helen provided strategic tax advice to publicly listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management. Helen has Bachelor degrees in Law (with Honours) and Science from the University of Melbourne, a Master’s degree in Laws (specialising in International Taxation) from the University of Melbourne and a Master’s degree in Commerce from the University of NSW. Helen is a Chartered Tax Adviser and an affiliate member of Chartered Accountants Australia and New Zealand. Helen is the Chair of the Victorian branch of AusBiotech. She was previously Non-Executive Director of Sienna Cancer Diagnostics Ltd (ASX:SDX).